AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Nov 17, 2026 ALTITUDE and AAVIATE eye-study registry updates Headline · Source: ClinicalTrials.gov registry
Nasdaq Global Select Market · $RGNXRetinal diseaseDuchenneClinical and financing risk

RGNX Stock Hub: REGENXBIO News, Retinal Trials and Duchenne Filing

REGENXBIO’s most immediate test is whether two pivotal studies with AbbVie can show that an investigational retinal treatment preserves vision against established care. September cash and securities reached $251.0 million after a milestone receipt and an equity offering, while quarterly revenue fell to $9.162 million. The company projects funding into late 2027 under its operating plan, and its September filing raises substantial doubt about its ability to continue as a going concern within twelve months of issuance of the financial statements. November clinical and financial update · September Form 10-Q, Note 1.

Last updated: November 19, 2026Financial period: quarter ended September 30, 2026Currency: U.S. dollars unless stated otherwise
Full research report · PDF
REGENXBIO Inc. ($RGNX), research updated November 19, 2026
19 pages on pivotal retinal trials, Duchenne, clinical holds, cash and royalty financing. For personal use only: redistribution prohibited.
Get the report (PDF)
Next company-guided readout
Fourth quarter 2026 · ATMOSPHERE and ASCENT

REGENXBIO and AbbVie expect topline data from both pivotal wet age-related macular degeneration studies in the fourth quarter. November trial timeline.

The September filing gives the fourth quarter for a pre-filing meeting on RGX-202 in Duchenne muscular dystrophy and the first quarter of 2027 for the planned application. Duchenne regulatory outlook.

REGENXBIO Inc. RGNX daily stock chart
Daily chart $RGNX. The chart link is an affiliate link. Interactive chart with bull and bear scenarios on JC Just Charts →

RGNX stock at a glance

Chart analysis · JC
Technical chart analysis of $RGNX with bull and bear scenarios on JC Just Charts.
Cash and marketable securities
$251.0 million
September 30, 2026, before October settlement cash. Company results.
Quarterly revenue
$9.162 million
Quarter ended September 30, 2026. Statement of operations.
Operating cash used
$99.815 million
Nine months ended September 30, 2026. Statement of cash flows.
Royalty-related debt
$185.678 million
September 30 carrying value. Note 7.
Common shares outstanding
66,122,600
October 30, 2026. Form 10-Q cover.
Short interest
10,179,714 shares
October 30, 2026 settlement. Nasdaq short interest.

Where REGENXBIO stands now

The company earns licensing and service revenue while developing its own candidates and programs with partners. AbbVie is its partner on surabgene lomparvovec, also called sura-vec, for retinal diseases. The Duchenne program is on a separate proposed filing timetable. RGX-121, the investigational treatment for Hunter syndrome, is on clinical hold. These programs differ in their evidence, commercial rights and effect on the balance sheet. Business and active clinical programs · November program update.

The balance sheet benefited from cash that arrived on distinct schedules. The AbbVie milestone was earned in June and collected in July. The September settlement with Sarepta generated a quarterly gain and a receivable that was paid in October. The company’s recurring licensing revenue, collaboration payments and operating cash requirements therefore need separate attention. Settlement, milestone and cash-flow notes.

Constructive case

Both pivotal eye studies preserve visual acuity against their controls, with an acceptable safety profile and fewer supplemental treatments. The Duchenne filing remains on schedule and the partners have the evidence they need to plan the next regulatory steps.

Cautious case

One readout disappoints on visual acuity, safety or retreatment. Regulatory work on Duchenne stretches beyond current guidance while cash from legacy royalties becomes less available to finance the operating plan.

Latest RGNX news

Nov 17, 2026

ALTITUDE and AAVIATE eye-study registry updates

The November 16 ALTITUDE record listed the study as completed. The November 17 AAVIATE record listed October 13 as actual primary completion and kept the study active without recruitment. These listings are separate from the anticipated pivotal wet AMD readouts.

Nov 11, 2026

REGENXBIO at the Stifel healthcare conference

The company listed a Stifel Healthcare Conference appearance for November 11. Its November 5 update gave a fourth-quarter window for two pivotal retinal readouts and a first-quarter 2027 target for the Duchenne filing.

Nov 10, 2026

State Street reports 4.8% beneficial ownership

The Schedule 13G reported 3,153,366 shares as of September 30 and indicated the holder had ceased to own more than 5%.

Nov 5, 2026

REGENXBIO’s September results and updated development timetable

The company reported $251.0 million in September cash and investments and confirmed the $39 million October settlement receipt. The 10-Q discloses substantial doubt about its ability to continue as a going concern within twelve months of issuance of the financial statements.

Oct 20, 2026

REGENXBIO presents its retinal development update

The company discussed preliminary observations and the pivotal wet AMD program at the October 20 investor event. The fourth-quarter topline readouts from ATMOSPHERE and ASCENT are separate milestones.

RGNX catalyst calendar

  • May 14 and June 24, 2026 — The company reported pivotal RGX-202 biomarker results and later announced completion of treatment in the confirmatory study. Reported clinical milestones · Pivotal announcement · Confirmatory update
  • June and July 2026 — The first NAAVIGATE participant received treatment in June. AbbVie paid the milestone in July. REGENXBIO priced an underwritten public offering on July 16, and the September filing reports it as completed in July. Earned milestone, received cash and completed financing · Notes 9 and 10 · July financing filing
  • August 24, 2026 — REGENXBIO announced a clinical hold on RGX-121 after new findings on spine imaging. Regulatory hold · August Form 8-K · Company notice
  • August 25, 2026 — The board elected Gregory Ciongoli as an independent Class II director, accepted the resignations of directors Jean Bennett and A.N. “Jerry” Karabelas, who will serve as advisors to the company until February 2027, and reduced the board to nine directors. Board change · August 25 Form 8-K
  • September 23–24, 2026 — The Sarepta patent settlement was announced, and REGENXBIO reported three-year ALTITUDE follow-up. The $39 million settlement receipt followed in October. Settlement and clinical follow-up · Settlement Form 8-K · September ALTITUDE follow-up · Note 8, October receipt
  • October 13–21, 2026 — JPMorgan filed an ownership report, REGENXBIO hosted its retinal investor event on October 20, and a Form 8-K filed October 16 reported that director Kenneth T. Mills had resigned effective October 21 and that George Migausky had been appointed Chairman. Reported ownership, conference and governance · JPMorgan Schedule 13G · October retinal presentation · Board filing
  • November 1–5, 2026 — Four November 1 equity awards were disclosed on November 3. Financial results and the September quarterly filing followed on November 5. Award and period report · Form 4 example · Quarterly results · Form 10-Q
  • November 10–11, 2026 — State Street filed a Schedule 13G reporting 4.8% of the shares at September 30, below the 5% threshold. The Stifel healthcare conference appearance followed in New York on November 11. Ownership filing and past investor event · State Street Schedule 13G · Conference event
  • November 16–17, 2026 — The ALTITUDE registry listed study completion, and the AAVIATE record reported primary completion. Registry updates · ALTITUDE · AAVIATE
  • Fourth quarter 2026 — Topline ATMOSPHERE and ASCENT results are expected with AbbVie. The company also expects a meeting with the U.S. Food and Drug Administration (FDA) before submitting its Duchenne application. Company-guided windows · November outlook
  • First quarter 2027 — REGENXBIO plans a Biologics License Application (BLA) for RGX-202 under the accelerated approval pathway. Submission target · Duchenne regulatory plan
  • First half of 2027 — The company expects to initiate AFFINITY RISE outside the United States. Planned randomized trial · November clinical plans
  • 2027 — Global regulatory submissions for sura-vec in wet age-related macular degeneration are planned. A possible second-half Duchenne approval is a company scenario. Company projections · November outlook
  • No company date — Follow-up and imaging review continue for RGX-121. The August announcement said resubmission was not expected in the near term. Open regulatory matter · Hold announcement · November status

Three programs and three kinds of evidence

Retinal disease

The two pivotal eye studies use an active comparator and a visual acuity outcome. The diabetic retinopathy program uses a separate study design and disease progression measure. Retinal program summary.

Duchenne

The lead result measures an intermediate biological response. The eventual application will also need evidence on function and safety. Pivotal disclosures.

Hunter syndrome

A Complete Response Letter and later clinical hold leave both evidence and safety questions open. FDA letter · August company announcement.

REGENXBIO Inc. deep dive: the full analysis

How the retinal readouts, Duchenne approval pathway, stalled rare-disease program and royalty-backed balance sheet fit together. The Merlintrader Research Library collects our dated biotech stock research reports.

01 Bull, base and bear scenarios

Bull scenario · The pivotal eye results support an application

The two studies produce consistent visual-acuity comparisons, with rescue and safety results that support a durable treatment option. The partners can then plan filings around a defined evidence package. A smooth Duchenne submission would add a separate opportunity at a time when the company needs to move from periodic milestone receipts toward more dependable income. In this case, a better licensing and development outlook helps the company approach future financing from a stronger operating position. Company projected milestones · Financial and regulatory risks.

Base scenario · The readouts advance development, with work still to do

REGENXBIO and AbbVie report results that permit continued development, while questions about specific populations, need for extra treatments or management of adverse events remain. The Duchenne application proceeds with questions about support for the proposed surrogate endpoint. Revenue continues to vary with license terms and achievement of milestones, and short-term operating and financing decisions remain important even with a fuller cash balance. Program, funding and collaboration discussion.

Bear scenario · Clinical or regulatory setbacks outlast the financing cushion

A pivotal retinal study shows weaker visual acuity or a less favorable rate of serious ocular complications. A request for additional Duchenne data pushes the schedule past the current target. With a smaller legacy royalty stream and commitments against future license proceeds, spending on several late-stage programs could force management to reduce activity or seek more capital. A longer clinical hold would also weigh on the timing of the Nippon Shinyaku collaboration. Liquidity note, debt and risk factors · Current RGX-121 hold.

What would falsify this reading

The retinal case depends on control-arm comparisons, not merely change from baseline in treated eyes. A failure to meet the prespecified noninferiority margin in either trial would weaken the central thesis. Meeting that margin with substantial extra treatments or a material safety imbalance could also displace the presumption of a lower treatment burden. Evidence of stable vision and lower retreatment across the relevant groups would provide a clearer test of the expected clinical trade-off. ATMOSPHERE record · ASCENT record.

The financial thesis also has a check. Future filings can show the company’s cash use between milestone receipts, actual financing commitments and how much royalty cash is available after payments to licensors and lenders. A large difference between activity assumed in the runway and activity needed for regulatory work would alter the financing requirement. A receipt after quarter end changes available resources on its payment date and does not change September’s balance sheet. Liquidity discussion and reporting dates.

02 Business model and operating exposures

REGENXBIO Inc. is a Delaware company headquartered in Rockville, Maryland. Its common stock is listed on the Nasdaq Global Select Market. The company describes three sources of activity: development of its own investigational products, joint programs under contract with partners, and licensing of intellectual property used by other companies. The resulting revenues include license fees, royalties and services. Novartis markets Zolgensma and Itvisma for spinal muscular atrophy under a license that generates some of those royalties. The partner’s sales are a separate figure from the fraction recognized by REGENXBIO. Form 10-Q cover and business description · Novartis quarterly disclosure.

The operating model matters for interpreting trial results. Under its retinal collaboration, REGENXBIO shares work and potential U.S. economics with AbbVie. Its own Duchenne program leaves more direct responsibility for regulatory and launch preparation. Nippon Shinyaku’s commercial rights in specified territories put the rare-disease programs on a third contractual path. Each program can require upfront spending before revenue or a milestone becomes available. The number of investigational programs is therefore a poor proxy for either the number of potential revenue streams controlled by the company or the cash it already has. Note 10, collaboration arrangements and operating model.

03 The next pivotal retinal results

In wet age-related macular degeneration (wet AMD), abnormal blood vessels under the central retina can leak and impair central vision. Existing medicines inhibit vascular endothelial growth factor (VEGF) and are given repeatedly according to the product and the patient’s disease course. Sura-vec is being studied as a one-time treatment intended to reduce the burden of repeated treatments. A comparison centered on visual acuity addresses whether vision can be maintained, while the number of supplemental injections addresses how often the intended change in burden is realized. Both matter when the intervention requires a different clinical setting from a routine injection. Retinal development program · Reference randomized studies in wet AMD.

The September filing reports that enrollment in ATMOSPHERE and ASCENT finished in October 2025. It describes more than 1,300 participants across more than 200 sites. The trial records list 671 participants for ATMOSPHERE and 735 for ASCENT. Both records describe a fellow-eye substudy. These are registry enrollment counts, and the analysis sets will be determined by the study reports. Both records list the trials as active without further recruitment. As of November 19, 2026, neither registry entry has posted trial results. The company’s fourth-quarter window is a forecast for the topline announcement rather than an exact event date. ATMOSPHERE study record · ASCENT study record · Company timetable.

Pivotal studyComparisonPrimary measureCompany reporting window
ATMOSPHERESura-vec versus ranibizumabBest-corrected visual acuity change at week 54Fourth quarter 2026
ASCENTSura-vec versus afliberceptBest-corrected visual acuity change at week 54Fourth quarter 2026

Both primary endpoints are tests of noninferiority. Under that design the difference and its confidence interval are compared with a prespecified margin for acceptable loss of efficacy. The direction and size of the interval matter alongside the reported average. Supplemental injections can be clinically appropriate and can help preserve vision after the initial treatment. The control-adjusted acuity outcome, the proportion needing rescue and the distribution of rescue visits are consequently distinct results. A low average number of visits can also hide a subgroup that needs repeated intervention. Primary and secondary outcome definitions · Active-controlled companion study · October overview of the clinical program.

Published Phase 3 evidence for existing treatments provides a useful standard for interpreting this design. Jeffrey S. Heier and colleagues reported TENAYA and LUCERNE in The Lancet in 2022. Faricimab met the trial criteria for noninferiority to aflibercept on visual acuity, with estimated differences of 0.7 and 0.0 letters, respectively. Those were different studies and a different therapy. They illustrate how efficacy and treatment interval can be assessed together under randomization. Patient populations, timing, study visits and the criteria for follow-up or supplemental treatment affect the comparison. The published numbers are useful context for the endpoint, without supplying an effect estimate for sura-vec. Heier et al., TENAYA and LUCERNE · REGENXBIO’s pivotal endpoints.

04 Earlier ocular evidence and what the later design adds

Peter A. Campochiaro and colleagues reported an earlier open-label Phase 1/2a study in The Lancet in 2024. It examined safety, visual findings and use of additional treatment in people with wet AMD who had previously received anti-VEGF therapy. The publication describes a reduction in treatment burden in some groups. It also describes ocular adverse effects, including a serious pigmentary change with vision loss in one participant in a higher-exposure group. With a small early-stage study, visual change from baseline and a patient’s previous treatment history are informative observations. They cannot substitute for active-controlled outcomes under a prespecified Phase 3 analysis. Campochiaro et al., Phase 1/2a results · Phase 3 design and development update.

REGENXBIO’s July 18, 2026 conference release looked further out in follow-up. It reported stable or improved acuity and less additional anti-VEGF treatment in selected groups followed to five years, with a stated exception for a participant whose associated retinal disorder responded poorly to prior treatment. Those are sponsor observations from the early program. The people who remain in a later visit can differ from those who leave follow-up. A report at five years is most useful when the number of participants remaining, earlier course and need for rescue are considered together. The pivotal trials will supply a substantially larger population and a different comparison. July long-term clinical disclosure · Follow-up discussion.

The company’s October 20 event also discussed complementary studies. ODYSSEY uses retrospectively matched real-world controls. AbbVie is enrolling ACHIEVE, a randomized Phase 3b study intended to examine treatment burden together with longer-term vision and safety in conditions closer to practice. Those studies can add context about patients who seek treatment and about visit requirements. The initial decision point is still the two prespecified pivotal comparisons. A commercial case also depends on training, capacity, referral, coverage and the mix of patients who would consider a procedure upfront to reduce later visits. October 20 investor event materials · Complementary studies and commercial risks.

Some secondary reports state that at the November 11 Stifel conference, management pointed to existing retinal surgery infrastructure and trained surgeons when discussing possible adoption of the retinal program. This account is not confirmed by a primary filing; readers can verify it in the reports linked here. Existing capacity helps frame the delivery question. Adoption would still depend on which groups have consistent outcomes, on monitoring needs and on what payers cover. Company event listing · Secondary report (minor site) · Commercial and coverage risks.

05 Diabetic retinopathy is a separate clinical and financial program

Diabetic retinopathy has a different course and clinical decision point from wet AMD. The recruiting NAAVIGATE trial is in adults with nonproliferative diabetic retinopathy without macular edema involving the center of the retina. Its randomized, masked design compares sura-vec with a simulated procedure. According to the trial record, the primary outcome is the proportion achieving an improvement of at least two steps on the Diabetic Retinopathy Severity Scale (DRSS) at week 52. The record estimates enrollment of 576 and primary completion in June 2028. The November Form 10-Q describes the endpoint as more than two steps. A protocol or statistical analysis plan accompanying results would clarify the threshold used for analysis. NAAVIGATE trial record · Form 10-Q clinical program.

ALTITUDE is earlier evidence. The September 24 sponsor report described 10 participants with three-year visits in the group discussed for the later study. Six of those ten achieved improvement of more than two DRSS steps without additional treatment for diabetic retinopathy. The November 16 registry update recorded completion on June 18, 2026, and 139 participants across groups. It carried no registry results. The six-person result describes a subset with available follow-up, and the sponsor’s report is a reason to study the effect rather than an estimate of response in all participants. A randomized comparison can separate natural changes in the retinopathy scale from the timing of follow-up and use of other care. September three-year results · ALTITUDE trial record · Randomized follow-on trial.

The first participant received treatment in NAAVIGATE in June 2026. That event met a contract condition for a $100 million AbbVie development milestone. The company recognized the revenue in the June quarter and received the payment in July. The first stage is expected to inform the expansion phase. AbbVie will lead a separate Phase 3 study and a second $100 million milestone is contingent on the first participant receiving treatment in that study. The trial can continue to use resources before the partners have an outcome to take to regulators. The milestone evidences contract execution and a cash receipt. Effectiveness and safety will be assessed from the clinical study data. Note 10, milestone accounting and clinical outlook · June quarter milestone recognition.

The subretinal wet AMD program and the suprachoroidal diabetic retinopathy program differ in administration setting, eligible population and outcome. They merit independent review even though they involve the same lead candidate. AAVIATE is yet another study, evaluating the latter ocular route in patients with wet AMD. Its registry lists 146 actual participants and primary completion on October 13, 2026. The November 17 registry update listed the trial as active without recruitment and estimated completion in February 2027. The November timeline for ATMOSPHERE and ASCENT is separate from both AAVIATE and NAAVIGATE. AAVIATE study record · Retinal program distinctions.

06 Duchenne evidence and the proposed filing

Duchenne muscular dystrophy progressively impairs muscle function. Motor assessments such as the North Star Ambulatory Assessment (NSAA) score tasks performed by children who can walk. Changes over a year may differ with age, baseline function and the expected progression of the condition. The RGX-202 pivotal primary analysis instead measured microdystrophin expression at week 12. The May 14 announcement said 93% of the 30 participants in the biomarker analysis reached the study’s 10% threshold relative to the dystrophin level in participants without Duchenne and reported p < 0.0001 for the primary endpoint. This tells reviewers about an intermediate biological response. The regulatory question is how well that measure predicts durable functional benefit. May pivotal results · AFFINITY DUCHENNE record.

REGENXBIO reported interim function at one year for nine participants, including NSAA and timed tests compared with external controls, and reported a correlation between expression and functional improvement. The company’s topline announcement also described two serious adverse events in the 31-person pivotal safety group, subacute myocarditis and an asymptomatic liver injury. According to the sponsor, both resolved within weeks. Those safety observations are from the pivotal group. The company separately reported no serious adverse events in 13 participants in its earlier Phase 1/2 group. The safety follow-up planned for the filing combines pivotal and confirmatory participants, while the efficacy data come from the pivotal portion. Pivotal denominators and events · Early-stage and pivotal follow-up.

The planned application illustrates why a biomarker at a single visit and longer clinical outcomes are distinct pieces of evidence. The company says it expects approximately 63 people to contribute safety data from the pivotal and confirmatory groups and expects to include one-year functional observations for at least half of its pivotal subjects. Its June 24 disclosure had planned to initiate the filing in the third quarter of 2026. The November 5 update guides to a fourth-quarter pre-BLA meeting and a first-quarter 2027 submission. The company describes a possible second-half 2027 approval under an accelerated pathway. In the September filing the sponsor said FDA recommended a randomized controlled trial and indicated that a sufficiently large treatment effect could make externally controlled evidence adequate for review. June plan and confirmatory study · Updated timeline and anticipated dataset.

The company also expects AFFINITY RISE, a randomized, placebo-controlled study outside the United States, to start in the first half of 2027. Its role would differ from the original open-label study and the external evidence used to interpret expected disease progression. A randomized control offers an opportunity to measure changes against participants receiving the same background follow-up. The need for an appropriate control matters because a young child can improve on some tasks even in a progressive disease, while an older child may already be entering a slower or declining phase. AFFINITY RISE plan · Randomized Duchenne outcomes and age context.

EMBARK provides a separate clinical precedent. Jerry R. Mendell and colleagues published the primary analysis in Nature Medicine (online in October 2024, volume 31, 2025). The group difference on the primary week-52 NSAA outcome for Sarepta’s therapy was 0.65 points, with a 95% confidence interval from −0.45 to 1.74 and p = 0.2441. The study did not meet that primary endpoint. Some other motor measures numerically favored treatment. The findings illustrate why observed biological activity and later motor comparisons require separate interpretation. Differences in study population, intervention and design preclude a ranking against RGX-202 from cross-trial results. Mendell et al., EMBARK primary analysis.

FDA changed Elevidys labeling in November 2025 to limit the indication to ambulatory patients at least four years old with a confirmed mutation in the DMD gene and added a boxed warning for serious liver injury and liver failure, including fatal outcomes. The action followed reports of fatal liver failure in nonambulatory patients. This safety history concerns a separate product and informs the care setting against which a new therapy could be assessed. REGENXBIO’s candidate has its own safety database and proposed eligible population. A broader potential population or early expression result is insufficient by itself to predict an eventual label. FDA labeling action · Licensed product and safety information · RGX-202 pivotal disclosure.

07 Hunter syndrome and the two regulatory episodes

Mucopolysaccharidosis type II (MPS II), also called Hunter syndrome, affects multiple organs and can involve progressive neurologic impairment. In a 2006 trial published in Genetics in Medicine, Joseph Muenzer and colleagues evaluated idursulfase enzyme replacement against placebo. They reported improvement on a composite involving walking and lung function after roughly a year. Those are systemic outcomes in a separate study. They help describe treatment options and the burden of disease. The RGX-121 application raised a distinct question about a candidate designed to address patients with neurologic involvement. Muenzer et al., clinical idursulfase trial · FDA response to the RGX-121 application.

REGENXBIO submitted its RGX-121 application seeking accelerated approval in March 2025. Its later sponsor update reported an 82% median reduction at one year in a cerebrospinal-fluid biomarker among the 13 participants in the pivotal CAMPSIITE group. FDA’s February 7, 2026 Complete Response Letter identified problems with defining a neuronopathic population, matching it with the natural-history comparison and establishing that the biomarker was reasonably likely to predict clinical benefit. The size of a biological change and its relationship to how patients function are distinct parts of the regulatory assessment. Sponsor timeline and biomarker result · Complete Response Letter · CAMPSIITE registry.

There were two different safety-related episodes. In January the company announced a partial hold on RGX-121 after a serious event in the separate RGX-111 study. FDA lifted that RGX-121 hold on April 30. After a formal dispute resolution request and discussions, REGENXBIO said in June and July that the agency had outlined a potential path to resubmission using the existing study population. On August 24 the company announced a new clinical hold on RGX-121 after spine magnetic resonance imaging (MRI) showed abnormalities in five CAMPSIITE participants who had no symptoms from those findings. REGENXBIO said in November that it continues to collect and evaluate imaging and longer-term observations. The August announcement said it did not expect resubmission in the near term. January company notice · April, June and July regulatory chronology · August clinical hold · November follow-up.

RGX-111 is an investigational treatment for mucopolysaccharidosis type I (MPS I), also known in its severe form as Hurler syndrome. Future development was halted in November 2023 during a pipeline prioritization, and efforts to continue it under the Nippon Shinyaku partnership are ongoing. The company reported a partial hold in January 2026 after a tumor was detected on routine imaging in one child treated in the original study. According to the September filing, an independent analysis found clonal integration of the viral vector into the PLAG1 gene in the tumor tissue, consistent with the hypothesis that this integration contributed to tumor formation. The filing also notes that the child had an unsuccessful stem cell transplant at four months of age and received chemotherapy that may have contributed to DNA damage. A single case can prompt rigorous follow-up without supplying an estimate of frequency among all treated patients. The two programs differ by disease and both matter under the Nippon Shinyaku collaboration. January program notice · Clinical assessment and collaboration.

08 How the partners share the economics

The AbbVie agreement helps explain why a pivotal retinal result matters to both companies. REGENXBIO received $370 million when the agreement took effect in November 2021. The agreement provides for up to about $1.38 billion in combined development and sales milestones, including the $100 million milestone received in July 2026. At September 30 the filing identified up to $462.5 million in remaining development milestones and up to $820.0 million tied to sales. The agreement has shared development costs. AbbVie leads global commercialization, and the parties would split U.S. net profits and losses equally. Outside the United States, REGENXBIO is eligible for tiered royalties. A milestone is tied to a contractual event and can bring cash before commercial use. Revenue under the U.S. arrangement would depend on commercial performance and the agreed cost and profit terms. AbbVie agreement and MD&A.

Note 10 shows a $7.425 million net cost reimbursement from AbbVie for the September quarter, down from $17.030 million a year earlier. The September-quarter figure reflects a $9.336 million reduction in recorded research and development expense and a $1.911 million increase in recorded general and administrative expense under the collaboration. These amounts are recorded in operating expense under the shared-cost accounting policy. The timing of payment by a partner and the treatment of the expense in the income statement can both affect comparisons across quarters. The June retinal milestone is separately reported under license and royalty revenue. AbbVie collaboration accounting and net cost recovery.

Nippon Shinyaku paid $110 million when the MPS collaboration took effect in March 2025. Its rights cover the United States and certain countries in Asia. REGENXBIO leads U.S. development and retains rights in territories outside the agreement. The contract contains up to $700 million tied to specified development and sales milestones and double-digit royalties on potential net sales, subject to offsets and reductions. REGENXBIO retains the rights to any priority review vouchers it may receive if statutory criteria are satisfied. The September quarter records $3.309 million in Nippon Shinyaku service revenue and no license or royalty revenue under that contract. The sponsor’s postponed resubmission and clinical hold matter for the timing of possible contingent proceeds. Note 10, Nippon Shinyaku operating responsibilities and service revenue · RGX-121 regulatory status.

Some receipts under Nippon Shinyaku and other arrangements are assigned to service the company’s royalty bond. A contract milestone can be earned while the cash available to REGENXBIO depends on the allocation of the payment. Services, up-front amounts and sales-based royalties also use different accounting rules. This difference is one reason headline collaboration maximums are unsuitable as measures of current liquidity. The debt and its claims on royalty proceeds are part of the same economic picture. Notes 7 and 10, assigned proceeds and revenue recognition.

09 Revenue and the September income statement

Third-quarter revenue fell to $9.162 million from $29.733 million. License and royalty revenue accounted for most of the decline. REGENXBIO attributed a $21.2 million decrease in Zolgensma royalties primarily to the January expiration of licensed U.S. patents. The September filing says the company retains royalty rights in countries where licensed patents remain active and may receive royalties on qualifying inventory made before expiration. Itvisma generated $2.8 million in royalties for the quarter, supported by patents in the United States and other territories. Novartis began U.S. sales in the first quarter of 2026, according to the November release. Royalties and U.S. sales launch · License-portfolio discussion.

U.S. dollars in thousands, except per-share dataQ3 2026Q3 20259M 20269M 2025
License and royalty revenue5,24423,605114,175129,119
Service revenue3,9186,1289,39910,985
Total revenues9,16229,733123,574140,104
Cost of license and royalty revenues1,1415,72513,25714,370
Research and development61,00956,101174,434168,688
General and administrative20,57920,25363,50160,483
Gain on litigation settlement38,026—38,026—
Other operating expense or benefit(7)6541125
Loss from operations(35,534)(52,411)(89,633)(103,562)
Interest expense(7,472)(13,169)(23,973)(32,732)
Total other income or expense(5,204)(9,530)(18,447)(23,167)
Net loss(40,738)(61,941)(108,080)(126,729)
Net loss per share, basic and diluted(0.62)(1.20)(1.90)(2.46)

The table presents the reported settlement gain as a positive amount. REGENXBIO’s statement shows it as a reduction of operating expenses. The $38.026 million gain is the $39 million claim against Sarepta net of amounts payable to certain licensors. The company recorded the receivable at September 30 and collected the $39 million in October. Removing that single gain from the reported quarterly operating result would leave a loss of $73.560 million, a Merlintrader calculation. It illustrates the size of the settlement’s effect on the period’s reported loss. Statement of operations and Note 8 · Settlement disclosure.

Research and development expense increased to $61.009 million in the quarter, from $56.101 million. The November release identifies higher costs for the RGX-202 trials as the primary reason. General and administrative expense remained closer to the prior-year level. Interest expense declined as the balance associated with the 2020 royalty agreement fell. The Novartis report records its own sales from the spinal muscular atrophy franchise, whereas the REGENXBIO income statement reflects royalties and licensing terms that apply to subsets of that business. Expense comparison · Novartis product sales · Note 7.

At September 30, REGENXBIO maintained a full valuation allowance against its deferred tax assets. The company attributed that judgment to its history of operating losses and other evidence about realizability. That allowance limits the recorded value of the tax assets in the financial statements. Note 12, income taxes.

10 Cash use, collections and the runway

At September 30 the balance sheet held $95.795 million in cash and equivalents and $155.181 million in marketable securities. Those two amounts total $250.976 million, a Merlintrader calculation. The December 2025 comparison was $34.466 million of cash, $195.604 million of current securities and $10.785 million of noncurrent securities, or $240.855 million by the same method. Restricted cash is reported separately. The June milestone was reflected in September cash after collection in July, while the October Sarepta receipt was still a September receivable. A reader should distinguish the balance-sheet date from the set of cash resources management used for its later outlook. Balance sheet, Note 1 and liquidity discussion.

Operations used $99.815 million in the first nine months of 2026, compared with $71.673 million in the first nine months of 2025. The June statements show use of $138.424 million and $15.713 million for the comparable six-month periods. The third-quarter differences are a $38.609 million inflow in 2026 and a $55.960 million outflow in 2025, both Merlintrader calculations. The $100 million AbbVie receipt fell in the 2026 quarter. Subtracting only that receipt from the 2026 quarterly difference gives a $61.391 million outflow, a Merlintrader calculation. The resulting figure describes one quarter without that one receipt. The figure still reflects timing items, notably the $39.0 million Sarepta payment, which was a September receivable collected in October. Nine-month statement of cash flows · Six-month statement.

Most of the investing inflow reflected maturities and sales of marketable debt securities. The public offering belongs in financing, which supplied $110.784 million net over the first nine months after other receipts and financing payments. Financing cash flows include $107.777 million in net offering proceeds and $17.196 million in repayments of royalty monetization liabilities net of interest. A financing inflow can extend the period available for trials without changing their costs or odds of eventual approval. Cash-flow lines and operating discussion.

The company expects the September cash and securities plus the October $39 million payment to support operations into the late fourth quarter of 2027. That estimate is based on its current plan and excludes new financing and material milestone payments. Note 1 and management’s discussion also say conditions raise substantial doubt about its ability to continue as a going concern within twelve months of issuance of the financial statements. Both statements come from the November filing. The earlier June report described expected funding into the fourth quarter of 2027 and stated an ability to meet obligations for at least twelve months from issuance. The September filing raises substantial doubt, a change from the June liquidity assessment. The pace of expenditure, ability to raise capital and outcome of development are consequential for meeting commitments. November Note 1 and MD&A · Earlier June liquidity discussion.

11 Royalty monetization and claims on future receipts

REGENXBIO reports two royalty financing obligations as debt. The September total of $185.678 million comprises $9.416 million from the December 2020 royalty purchase agreement and $176.262 million for the May 2025 royalty bond. The balance sheet classifies $12.114 million as current and $173.564 million as noncurrent. Each amount is a carrying value under the accounting policy. The financing arrangements also specify the sources of cash applied to those obligations, which can differ from how the same royalties appear in the income statement. Note 7, balances and maturity classifications.

The 2020 agreement with entities managed by Healthcare Royalty Management, LLC (HCR) conveyed a capped portion of the Novartis royalty stream. HCR paid $196 million after a contractual adjustment for royalty proceeds. The earlier cap expired unmet in November 2024. Under the current cap of $300 million, covered royalties go to HCR net of certain upstream obligations until the cap is reached or the license terminates, whichever comes first. If the license terminates before covered royalty receipts reach the cap, the agreement has no shortfall repayment obligation. The expected amount and timing of royalties affect the estimated effective interest rate and carrying value. 2020 royalty purchase agreement.

The 2025 royalty bond has up to $250 million of nominal capacity. The first $150 million was funded in May 2025, with $144.5 million of net proceeds to the company before the accounting allocation between debt and warrants. A $50 million tranche depends on a specified commercial condition before December 31, 2026. Another $50 million requires both parties to exercise an option in 2027. The interest rate is 9.75% plus three-month Secured Overnight Financing Rate (SOFR) with a minimum of 14.0%. Specified royalty and other licensing proceeds fund quarterly interest and then principal. Unpaid interest increases principal. The nine-month roll-forward includes $17.770 million of unpaid interest accrued to principal and $1.147 million of discount and issuance-cost amortization. 2025 royalty bond terms and carrying-value bridge.

The second agreement includes certain proceeds from the Nippon Shinyaku collaboration and other specified licenses. Covered Novartis royalties enter the second agreement only after the earlier cap has been fully repaid. The current maturity is May 2035 with a possible extension to May 2037 tied to a patent condition. Note 7 says outstanding principal and interest are payable at maturity, with an additional final payment equal to 5% of applicable outstanding principal. The agreement restricts prepayments outside the assigned cash flows. A lower royalty stream can reduce near-term cash paid to HCR while increasing the amount of unpaid interest under the bond. A contractual ceiling or an obligation’s book value cannot by itself show the amount of future cash available from the licensed products. Collateral, repayment waterfall and maturity.

12 Equity financing, ownership and short interest

The July underwritten offering comprised 11,671,139 common shares at a contractual $9 each and 1,111,111 pre-funded warrants at $8.9999 each, with a remaining exercise price of $0.0001 per share. The prospectus covered 10,003,889 firm shares, and the July 20 Form 8-K reports that the underwriters exercised their option for another 1,667,250 shares on July 17, which brings the total to the 11,671,139 shares reported in the 10-Q (Merlintrader calculation). REGENXBIO recorded $107.777 million of net proceeds. At September 30 it reported 1,980,714 pre-funded warrants outstanding across the March 2024 and July 2026 offerings. The instruments have no expiry and impose holder-specific beneficial ownership limits. The filing classifies the warrants as equity without periodic remeasurement. The nominal-price warrants already enter the weighted-average denominator for earnings per share. Exercise can increase the reported share count while adding very little new cash. The same instrument belongs in different parts of a cash bridge and a dilution analysis. Form 10-Q, Note 9 · July offering prospectus · July 20 Form 8-K.

The separate $150 million at-the-market facility supplied about $18.9 million net on 2,318,735 shares in the second quarter, with no additional sales in the third quarter. The weighted-average count used for earnings per share describes shares applicable to the period and differs from the period-end count. Common shares outstanding were 50.892 million at December 31, 2025, 54.164 million at June 30 and 66.119 million at September 30, using the balance-sheet figures rounded to thousands. The October 30 cover count was 66,122,600. The rise matters when comparing a potential partnership milestone or future earnings with a prior reporting period on a per-share basis. September accounts and cover · June Form 10-Q.

The company disclosed approximately 10.558 million outstanding options at September 30, of which 6.957 million were exercisable, plus 2.884 million unvested restricted stock units and 306,000 unvested performance stock units. A July 2 exchange canceled 1,940,394 eligible options and issued 775,401 replacement options with an exercise price of $13.28. The 2025 royalty bond also led to the issuance of warrants over 268,096 shares at a contractual $14.92 exercise price. The HCR warrants have a ten-year term and are classified as equity without remeasurement. None had been exercised at September 30. Vesting, exercises and settlements differ by security, which is why the gross count of outstanding awards is a useful starting point for dilution analysis. Notes 7, 9 and 11 · July option exchange filing.

Four November 3 Forms 4 disclosed restricted stock unit grants dated November 1. Craig Malzahn received 27,777 units, Patrick J. Christmas and Steve Pakola each received 34,722, and Mitchell Chan received 24,305. The awards vest in annual thirds from 2027 through 2029 subject to continued service. Each filing uses transaction code A for the award. The dates, amounts and nature of the awards are separate from quarterly option exercises or transactions for cash in the market. Malzahn Form 4 · Christmas Form 4 · Pakola Form 4 · Chan Form 4.

Two ownership notices use September 30 as their reporting date. JPMorgan Chase & Co. reported 3,560,915 shares, or 5.3%, in an October 13 Schedule 13G. State Street Corporation reported 3,153,366 shares, or 4.8%, in a November 10 Schedule 13G that checked the box for ceasing to beneficially own more than 5%. The percentages and bases belong to each filing. A threshold crossing can reflect the numerator or the denominator and can also reflect ownership attribution across affiliated funds. October 13 ownership filing · November 10 ownership filing.

Nasdaq reported 10,179,714 shares short for the October 30 settlement, with average daily volume of 1,228,106 and 8.29 days to cover. The October 15 observation showed 10,043,670 shares short, average daily volume of 1,482,288 and 6.78 days to cover. Both higher short interest and a lower volume denominator contributed to the change in the ratio. These are dated settlement observations. The Financial Industry Regulatory Authority (FINRA) scheduled the November 13 settlement data for release on November 24. Nasdaq short interest · FINRA schedule.

13 Legal exposure, principal red flags and valuation

The September filing describes a putative securities class action filed February 13, 2026, in the U.S. District Court for the District of Maryland, case 8:26-cv-00611-DKC. The original complaint addressed RGX-111 disclosures. According to Note 8, an amended complaint filed in August makes allegations about disclosures concerning RGX-121 and its regulatory review under federal securities law. Separately filed derivative actions tied to RGX-111 were consolidated and stayed in June pending resolution of the planned motion to dismiss in the securities action. Management said it did not consider a loss probable and could not reasonably estimate a range as of September 30. It recorded no related liability. Court-filed February complaint (copy hosted by a third party) · September Form 10-Q, Note 8.

The September patent settlement with Sarepta is a different matter. It ended the specified patent actions with prejudice and covers particular patents and products; its financial effect is described in chapter 09. The equity holders’ lawsuits and the obligations in the HCR royalty agreements require separate assessment. September 23 Form 8-K · Contingencies and royalty financing.

Merlintrader reading: value depends on the quality of the pivotal evidence, the ability to fund the next development and commercial steps, and REGENXBIO’s contractual share of cash generated by any program. The retinal trials need a result that retains vision while delivering a meaningful reduction in treatment burden over time. The Duchenne filing adds the questions of surrogate validity, clinical function and safety. The Hunter program remains exposed to clinical hold and resubmission risk. Treating all three as though they share a single probability of success would obscure the differences in trial design and FDA status. Quarterly program update · FDA complete response letter.

On the financial side, collaboration receipts help finance the research program when milestones are achieved. The expense base and timing of those receipts explain why a single strong cash-flow quarter has limited use as an estimate of recurring economics. Existing claims on royalties, additional equity issuance and the cost of a launch can each affect the cash available to common shareholders. The next readout therefore answers a clinical question first. Subsequent data on the development and regulatory plan, partner obligations and funding would be needed to assess the scale and timing of any economic benefit. Liquidity, program costs and contractual claims.

Merlintrader Health Score · $RGNX

2.75out of 5
Balance sheet and runway · 30%2.0 / 5

September cash and investments of $251.0 million and the October Sarepta receipt strengthen immediately available resources. Royalty-linked debt and an explicit substantial-doubt disclosure constrain the score despite management’s cash forecast into late fourth-quarter 2027. Notes 1, 7 and 8 · Management’s forecast.

Catalysts · 30%4.0 / 5

Two pivotal retinal readouts are expected in the fourth quarter of 2026, followed by a first-quarter 2027 Duchenne filing target. RGX-121 remains on clinical hold with no near-term resubmission anticipated. Clinical and regulatory guidance · August hold and resubmission notice.

Dilution · 20%2.0 / 5

Outstanding common shares increased from 50.892 million at year-end 2025 to 66.119 million in September, an increase of 29.9% (Merlintrader calculation). Pre-funded warrants, compensation instruments and an available at-the-market program add potential dilution. Balance sheet and Notes 9 and 11 · July prospectus.

Trading liquidity · 10%2.5 / 5

REGENXBIO is listed on the Nasdaq Global Select Market. The October 30 short balance of 10.18 million shares equaled 8.29 days of reported average volume, above the previous 6.78 days. Listing on filing cover · Nasdaq observations.

Execution · 10%3.0 / 5

The pivotal retinal trials completed enrollment in October 2025, the Duchenne confirmatory study finished dosing in June and REGENXBIO received the $100 million AbbVie milestone in July. Against that, FDA issued a Complete Response Letter for RGX-121 on February 7, a new clinical hold followed on August 24, and the Duchenne application moved from a third-quarter 2026 start (June 24 plan) to a first-quarter 2027 submission (November 5 update). Merlintrader reading: milestones met and setbacks roughly offset, which keeps the pillar at the midpoint. Collaboration accounting and program progress · Duchenne study update · FDA complete response letter · August clinical hold · November outlook.

Reassessed November 19, 2026. Merlintrader calculation gives 2.0 × 30% + 4.0 × 30% + 2.0 × 20% + 2.5 × 10% + 3.0 × 10% = 2.75 out of 5.

RGNX red flags

  • Vision and treatment burden can tell different stories. Rescue treatment and missing data matter when interpreting the retinal primary endpoint. Pivotal trial design.
  • Reported runway carries meaningful uncertainty. The Q3 cash bridge includes a milestone and an equity offering. The going-concern disclosure warrants separate attention alongside the cash forecast. Cash use and runway.
  • RGX-121 remains on hold. The August decision came after earlier alignment on the scope of a potential resubmission. There is no announced replacement filing date. Rare-disease programs.
  • Gross royalties can overstate cash retained. Two agreements direct portions of qualifying proceeds to HCR under distinct terms. Royalty obligations.
  • Equity funding changes each share’s claim on future results. The offering, awards and warrants should be tracked separately. Capitalization and ownership.

RGNX Stock FAQ: REGENXBIO Inc. Questions Answered

What is the next REGENXBIO stock catalyst?

REGENXBIO expects to report topline results from ATMOSPHERE and ASCENT in the fourth quarter of 2026. In wet age-related macular degeneration, ATMOSPHERE compares investigational surabgene lomparvovec with ranibizumab, and ASCENT compares it with aflibercept. ATMOSPHERE registry · ASCENT registry. November results and clinical calendar.

When does REGENXBIO expect to file RGX-202 with the FDA?

REGENXBIO plans to submit the RGX-202 application in the first quarter of 2027, according to its November 5, 2026, update. The investigational Duchenne candidate also has a pre-filing meeting targeted for the fourth quarter of 2026. FDA review would follow a filing and acceptance. Company regulatory timetable.

How much cash does REGENXBIO have?

REGENXBIO reported $251.0 million in cash, cash equivalents and marketable securities at September 30, 2026. It received $39 million from the Sarepta settlement in October. Management projects resources into late fourth-quarter 2027 under its assumptions, while the September filing carries a substantial-doubt disclosure. Form 10-Q, Notes 1 and 8.

What can dilute REGENXBIO common shareholders?

REGENXBIO issued 11,671,139 common shares, including the underwriters’ option exercised in full on July 17, and 1,111,111 pre-funded warrants in its July 2026 public offering. Exercise of warrants and options, vesting or settlement of equity awards, and additional offerings can increase shares outstanding. Equity notes · July prospectus · July 20 Form 8-K.

When did REGENXBIO report its latest earnings?

REGENXBIO reported third-quarter results on November 5, 2026, including revenue of $9.162 million and a net loss of $40.738 million. Results exhibit.

What does REGENXBIO do?

REGENXBIO develops investigational gene therapies for retinal and rare diseases, according to its November 5, 2026, filing. It also has collaboration and licensing arrangements that can produce service revenue, royalties or milestones under the respective agreements. Business description and Note 10.

Why is REGENXBIO’s RGX-121 on clinical hold?

REGENXBIO announced a new clinical hold on RGX-121 on August 24, 2026, after asymptomatic spinal imaging findings in five CAMPSIITE participants. The August notice said the company did not expect near-term resubmission. In November it said it continued to evaluate imaging and follow-up data. August Form 8-K · September Form 10-Q.

RGNX sources

Disclaimer. This content is published by Merlintrader for educational and informational purposes only. It is independent journalism and research. It does not constitute investment advice, an investment recommendation, an offer or a solicitation to buy or sell any security, and it is not a research report within the meaning of applicable United States securities regulation. Nothing here should be read as a recommendation to buy, sell or hold $RGNX or any other security.

Figures are taken from public filings with the U.S. Securities and Exchange Commission, company press releases, court records and market-data providers, and are stated with their reference dates. Data can change without notice. Readers should verify every figure against the primary source before acting on it.

Biotechnology and pharmaceutical companies carry clinical, regulatory, commercial and financing risk, including dilution, and readers can lose capital. Readers are responsible for their own decisions and should consult a licensed financial adviser where appropriate.

Merlintrader may hold positions in securities mentioned. Some links on this page are affiliate or referral links, including those to Finviz, which may generate a commission at no cost to the reader. Full legal information is available on the disclaimer and terms of use and privacy pages.